A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma

Completed · Phase 1

Conditions studied: Sarcoma, Kaposi, HIV Infections

In brief

To assess toxicity and determine the MTD of intravenous TNP-470 administered weekly in patients with AIDS-related Kaposi's sarcoma. To assess pharmacokinetics and tumor response of the drug. Since evidence shows that neovascularization is important in the development of Kaposi's sarcoma, drugs that inhibit angiogenesis, such as TNP-470, may be of benefit in patients with the disease.

Key facts

Study ID

NCT00000763

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

42

Expected to finish

1997-02-01

Last updated by the study team

2021-11-03

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• AZT, ddI, ddC, or d4T provided patients have received at least 2 weeks of this therapy prior to study entry. (Combination ddI/ddC is not permitted.)
• MAI prophylaxis.
• Required in patients with CD4 count < 200 cells/mm3:
• Aerosolized pentamidine, trimethoprim/sulfamethoxazole, or dapsone as PCP prophylaxis.
• Patients must have:
• HIV infection.
• Cutaneous Kaposi's sarcoma.
• Life expectancy of at least 3 months.
• Consent of parent or guardian if under 18 years of age.
• NOTE:
• This protocol is considered suitable for prison populations.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Peripheral neuropathy (grade 2 or worse).
• Underlying severe or life-threatening infection with bacterial, viral, fungal, or protozoal pathogens.
• Known hypersensitivity to TNP-470, fumagillin, or known related compounds.
• PER AMENDMENT 9/3/96:
• Cataracts.
• Concurrent Medication:
• Excluded:
• Combination therapy with ddI/ddC (although these drugs may be administered alone or in combination with AZT).
• Anticonvulsive medication.
• Steroids.
• Antineoplastic drugs.
• Interferons.
• Systemic or topical anti-Kaposi's sarcoma agents or regimens.
• Suramin.
• Aspirin.
• Warfarin.
• Heparin (including heparin flushes).
• Nonsteroidal anti-inflammatory drugs.
• Investigational status drugs.
• Patients with the following prior conditions are excluded:
• History of substantial non-iatrogenic bleeding disorders.
• History of tumor or malignancies other than Kaposi's sarcoma, with the exception of completely resected basal cell skin carcinoma or in situ cervical carcinoma.
• History of seizures within the past 10 years.

Where it is running

• USC CRS — Los Angeles, California, United States
• Northwestern University CRS — Chicago, Illinois, United States
• Bmc Actg Crs — Boston, Massachusetts, United States
• Beth Israel Deaconess - East Campus A0102 CRS — Boston, Massachusetts, United States
• Washington U CRS — St Louis, Missouri, United States
• Beth Israel Med. Ctr. (Mt. Sinai) — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.